{
    "organizations": [],
    "uuid": "11311673d274aa3cda1b060e3d74472152cf5303",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-mologen-signs-license-deal-for-chi/brief-mologen-signs-license-deal-for-china-with-oncologie-for-lead-compound-lefitolimod-idUSASM000J95",
    "ord_in_thread": 0,
    "title": "Mologen Signs License Deal For China With Oncologie For Lead Compound Lefitolimod",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 13 (Reuters) - MOLOGEN AG:\n* SIGNS LICENSE DEAL FOR CHINA AND GLOBAL CO-DEVELOPMENT AGREEMENT WITH ONCOLOGIE FOR LEAD COMPOUND LEFITOLIMOD\n* SIGNED AGREEMENT IS CONDITIONAL UPON AN INITIAL PAYMENT OF EUR 3 MILLION RECEIVED BY MOLOGEN\n* TOTAL PAYMENTS CAN AMOUNT TO ABOVE EUR 100 MILLION AND WILL BE PAID OVER SEVERAL YEARS\n* ADDITIONALLY, MOLOGEN WILL RECEIVE LOW DOUBLE DIGIT ROYALTIES ON SALES Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-02-13T23:18:00.000+02:00",
    "crawled": "2018-02-14T12:18:04.020+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "mologen",
        "ag",
        "sign",
        "license",
        "deal",
        "china",
        "global",
        "agreement",
        "oncologie",
        "lead",
        "compound",
        "lefitolimod",
        "signed",
        "agreement",
        "conditional",
        "upon",
        "initial",
        "payment",
        "eur",
        "million",
        "received",
        "mologen",
        "total",
        "payment",
        "amount",
        "eur",
        "million",
        "paid",
        "several",
        "year",
        "additionally",
        "mologen",
        "receive",
        "low",
        "double",
        "digit",
        "royalty",
        "sale",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}